Have a feature idea you'd love to see implemented? Let us know!

NTLA Intellia Therapeutics Inc

Price (delayed)

$14.81

Market cap

$1.5B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.48

Enterprise value

$1.48B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The company's debt fell by 13% YoY and by 4.1% QoQ
The company's quick ratio fell by 27% YoY and by 21% QoQ
Intellia Therapeutics's revenue has decreased by 13% YoY and by 13% QoQ

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
101.58M
Market cap
$1.5B
Enterprise value
$1.48B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.47
Price to sales (P/S)
31.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.19
Earnings
Revenue
$45.97M
EBIT
-$508.8M
EBITDA
-$498.93M
Free cash flow
-$382.65M
Per share
EPS
-$5.48
Free cash flow per share
-$3.95
Book value per share
$10.07
Revenue per share
$0.47
TBVPS
$12.29
Balance sheet
Total assets
$1.19B
Total liabilities
$220.47M
Debt
$106.3M
Equity
$971.06M
Working capital
$652.12M
Liquidity
Debt to equity
0.11
Current ratio
7.21
Quick ratio
6.69
Net debt/EBITDA
0.05
Margins
EBITDA margin
-1,085.4%
Gross margin
100%
Net margin
-1,106.9%
Operating margin
-1,140%
Efficiency
Return on assets
-40.7%
Return on equity
-49.7%
Return on invested capital
-46.9%
Return on capital employed
-46.8%
Return on sales
-1,106.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
4.15%
1 week
-7.15%
1 month
-22.86%
1 year
-41.92%
YTD
-51.43%
QTD
-27.93%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$45.97M
Gross profit
$45.97M
Operating income
-$524.05M
Net income
-$508.8M
Gross margin
100%
Net margin
-1,106.9%
Intellia Therapeutics's operating margin has decreased by 31% YoY and by 16% QoQ
The company's net margin fell by 29% YoY and by 20% QoQ
The company's operating income fell by 14% YoY
Intellia Therapeutics's revenue has decreased by 13% YoY and by 13% QoQ

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
1.47
P/S
31.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.19
The EPS has contracted by 2.2% from the previous quarter
The stock's P/B is 72% below its 5-year quarterly average of 5.3 and 41% below its last 4 quarters average of 2.5
Intellia Therapeutics's equity has decreased by 12% YoY and by 6% from the previous quarter
The price to sales (P/S) is 68% lower than the 5-year quarterly average of 96.5 and 45% lower than the last 4 quarters average of 56.5
Intellia Therapeutics's revenue has decreased by 13% YoY and by 13% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has contracted by 29% YoY and by 20% from the previous quarter
The ROA has contracted by 20% YoY and by 7% from the previous quarter
Intellia Therapeutics's ROE has decreased by 19% YoY and by 8% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 9% YoY and by 8% from the previous quarter

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
The company's quick ratio fell by 27% YoY and by 21% QoQ
NTLA's current ratio is down by 23% year-on-year and by 20% since the previous quarter
The company's debt is 89% lower than its equity
The company's debt fell by 13% YoY and by 4.1% QoQ
Intellia Therapeutics's equity has decreased by 12% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.